Research programme: enterovirus D68 RNA vaccines - HDT Bio
Latest Information Update: 22 Jul 2022
At a glance
- Originator HDT Bio
- Class RNA vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Enterovirus infections
Most Recent Events
- 20 Jul 2022 HDT Bio receives phase II SBIR grant from the NIAID of the National Institutes of Health for RNA vaccine development in Enterovirus D68 infections
- 03 Sep 2021 HDT Bio receives phase I SBIR grant from the NIAID of the National Institutes of Health for RNA vaccine development in Enterovirus D68 infections
- 03 Sep 2021 Preclinical development in Enterovirus infections (Prevention) in USA (IM)